Rini Mulia Sari

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 9

Top Topics

Protein Protein

Chronic Kidney Disease

Top Venues

Clinical and experimental vaccine research

This page only lists publications with an associated author ORCID identifier.

Publications

Henhen Heryaman, Cep Juli, Arnengsih Nazir, Mas Rizky Anggun Adipurna Syamsunarno, Badrul Hisham Yahaya, Dewi Kartika Turbawaty, Rini Mulia Sari, Hikmat Permana, Rudi Supriyadi, Nur Atik
Immunogenicity, Safety, and Efficacy of Influenza Vaccine in T2DM and T2DM with Chronic Kidney Disease. Vaccines 12 (3) (2024)
Henhen Heryaman, Cep Juli, Arnengsih Nazir, Mas Rizky Anggun Adipurna Syamsunarno, Badrul Hisham Yahaya, Dewi Kartika Turbawaty, Rini Mulia Sari, Hikmat Permana, Rudi Supriyadi, Nur Atik
Immunogenicity, Safety, and Efficacy of Influenza Vaccine in T2DM and T2DM with Chronic Kidney Disease. Vaccines 12 (3) (2024)
Eddy Fadlyana, Kusnandi Rusmil, Muhammad Gilang Dwi Putra, Frizka Primadewi Fulendry, Nitta Kurniati Somantri, Alvira Dwilestarie Putri, Rini Mulia Sari, Mita Puspita, Gianita Puspita Dewi
Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac ® ) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents. Vaccines 12 (8) (2024)
Henhen Heryaman, Cep Juli, Arnengsih Nazir, Mas Rizky Anggun Adipurna Syamsunarno, Badrul Hisham Yahaya, Dewi Kartika Turbawaty, Rini Mulia Sari, Hikmat Permana, Rudi Supriyadi, Nur Atik
Immunogenicity, Safety, and Efficacy of Influenza Vaccine in T2DM and T2DM with Chronic Kidney Disease. Vaccines 12 (3) (2024)
Sharifah Shakinah, Muhammad Hafiz Aini, Rini Sekartini, null Soedjatmiko, Bernie Endyarni Medise, Hartono Gunardi, Irene Yuniar, Wahyuni Indawati, Sukamto Koesnoe, Kuntjoro Harimurti, Suzy Maria, Angga Wirahmadi, Rini Mulia Sari, Lilis Setyaningsih, Fikrianti Surachman
Immunogenicity Assessment of the SARS-CoV-2 Protein Subunit Recombinant Vaccine (CoV2-IB 0322) in a Substudy of a Phase 3 Trial in Indonesia. Vaccines 12 (4) (2024)
Sharifah Shakinah, Muhammad Hafiz Aini, Rini Sekartini, null Soedjatmiko, Bernie Endyarni Medise, Hartono Gunardi, Irene Yuniar, Wahyuni Indawati, Sukamto Koesnoe, Kuntjoro Harimurti, Suzy Maria, Angga Wirahmadi, Rini Mulia Sari, Lilis Setyaningsih, Fikrianti Surachman
Immunogenicity Assessment of the SARS-CoV-2 Protein Subunit Recombinant Vaccine (CoV2-IB 0322) in a Substudy of a Phase 3 Trial in Indonesia. Vaccines 12 (4) (2024)
Eddy Fadlyana, Kusnandi Rusmil, Meita Dhamayanti, Rodman Tarigan, Cissy B Kartasasmita, Rini Mulia Sari, Muhammad Gilang Dwi Putra, Hadyana Sukandar
Comparison of Immunogenicity and Safety of Diphtheria-Tetanus-Pertussis-Hepatitis B- Haemophilus influenza B (Bio Farma) with Pentabio ® Vaccine Primed with Recombinant Hepatitis B at Birth (Using Different Source of Hepatitis B) in Indonesian Infants. Vaccines 11 (3) (2023)
Eddy Fadlyana, Kusnandi Rusmil, Meita Dhamayanti, Rodman Tarigan, Cissy B Kartasasmita, Rini Mulia Sari, Muhammad Gilang Dwi Putra, Hadyana Sukandar
Comparison of Immunogenicity and Safety of Diphtheria-Tetanus-Pertussis-Hepatitis B- Haemophilus influenza B (Bio Farma) with Pentabio ® Vaccine Primed with Recombinant Hepatitis B at Birth (Using Different Source of Hepatitis B) in Indonesian Infants. Vaccines 11 (3) (2023)
Yetty M Nency, Farid Agung Rahmadi, Mulyono, Dimas Tri Anantyo, Nur Farhanah, Rebriarina Hapsari, Helmia Farida, Udadi Sadhana, Tri Nur Kristina, Achmad Zulfa Juniarto, Mita Puspita, Rini Mulia Sari, Novilia Sjafri Bachtiar
Protectivity and safety following recombinant hepatitis B vaccine with different source of bulk compared to hepatitis B (Bio Farma) vaccine in Indonesia. Clinical and experimental vaccine research 11 (1) (2022)